Dosage and usage of Remibrutinib-RHAPSIDO

Remibrutinib - RHAPSIDO is a medicine indicated for the treatment of chronic spontaneous urticaria (CSU) in adult patients, particularly those who remain symptomatic despite receiving H1 antihistamine therapy. It is important to note that remibrutinib is not suitable for other types of urticaria.

In terms of usage and dosage, the recommended dose of remibrutinib is 25 mg per day divided into two doses. Patients can choose to take the drug after or before a meal, swallowing the remibrutinib tablets with water. It is important that patients avoid cutting, crushing or chewing the tablets to ensure the effectiveness and safety of the medication.

If a patient misses a dose of remibrutinib, they are advised to skip the untaken dose and take the next dose at the normally scheduled time. Additional doses of remibrutinib should not be taken to make up for a missed dose to avoid overdose.

In addition, patients need to consider the impact of the use of remibrutinib on the risk of bleeding when undergoing surgery or other invasive procedures. Depending on the type of surgery and associated bleeding risk, it is recommended to temporarily interrupt remibrutinib treatment before and after surgery, usually for 3 to 7 days, to reduce the possibility of bleeding.

In summary, the usage and dosage of remibrutinib must strictly follow the doctor's instructions, and ensure that patients pay attention to the accuracy of the dose and the timing of taking the drug. At the same time, patients should communicate with their medical provider in advance before undergoing surgery to ensure that medication use and potential bleeding risks are managed safely. Through rational medication strategies, patients can better control the symptoms of chronic spontaneous urticaria and improve their quality of life.

Reference materials:https://www.drugs.com/rhapsido.html